MedTrace Logo

An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

NCT02552940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2018-05-11

No results posted yet for this study

Summary

This observational trial will evaluate the effectiveness, the consistency of evaluation scores, quality of life, safety and tolerability of TCZ administered subcutaneously (SC) in participants with RA in daily clinical practice.

Conditions

Interventions

DRUG

Tocilizumab

Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-10-23
Completion
2017-10-23

Countries

  • Belgium
  • Luxembourg

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02552940 on ClinicalTrials.gov